Lars Ny - Publications

Nodal localisation with magnetic seed in patients with stage III melanoma receiving neoadjuvant immune checkpoint inhibitors, a feasibility study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: April 20, 2026

Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2026

Neoadjuvant immunotherapy for resectable cutaneous melanoma: a nationwide population-based cohort.

Journal: Journal of the National Cancer Institute

Published: March 11, 2026

Neoadjuvant Immunotherapy Using PD-1 Inhibitors for Resectable Stage III Cutaneous Melanoma-Different Outcomes Between Patients With Lymph Node and In-transit Metastases.

Journal: Annals of surgery

Published: February 06, 2026

SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 17, 2025

New directions in combination treatment of uveal melanoma with liver metastases.

Journal: The Lancet. Oncology

Published: December 17, 2025

Longitudinal ctDNA monitoring in patients with metastatic uveal melanoma undergoing isolated hepatic perfusion in combination with ipilimumab and nivolumab.

Journal: Immuno-oncology technology

Published: December 09, 2025

PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.

Journal: Immunotherapy advances

Published: November 27, 2025

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.

Journal: BMC cancer

Published: September 30, 2025

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 15, 2025

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab.

Journal: Oncoimmunology

Published: August 08, 2025

Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.

Journal: Journal of the National Cancer Institute

Published: July 24, 2025